Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | HTR7 | P34969 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306493 | 0.94 | F10 (0.43) | F10HTR1ADRD2HTR7MAPT | |
| SCHEMBL4302294 | 0.93 | MAPT (0.42) | F10HTR1ADRD2HTR7MAPT | |
| SCHEMBL4302265 | 0.91 | F10 (0.44) | F10HTR1ADRD2HTR7MAPT | |
| SCHEMBL4309841 | 0.90 | RPS6KA2 (0.44) | F10HTR1ADRD2MAPTHTR2A | |
| SCHEMBL4313299 | 0.89 | HTR1A (0.43) | F10HTR1ADRD2HTR7ADRA1D | |
| SCHEMBL4306062 | 0.88 | HTR2A (0.42) | HTR1ADRD2HTR7HTR2AHTR2C | |
| SCHEMBL4307569 | 0.88 | MAPT (0.43) | F10DRD2HTR7MAPTHTR2A | |
| SCHEMBL4307192 | 0.87 | MAPT (0.43) | HTR1ADRD2HTR7MAPTLMNA | |
| SCHEMBL4309292 | 0.86 | F10 (0.39) | F10HTR1ADRD2HTR7HTR2A | |
| SCHEMBL4310904 | 0.86 | L3MBTL1 (0.45) | MAPTLMNAKDM4EMAPK1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482472-B2 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20080039446-A1 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-7189738-B2 | Substituted isoindoles and their use thereof | BAYER HEALTHCARE AG (DE) | 2007-03-13 | — | — | US | disclosed |
| EP-1414817-B1 | substituted isoindoles and the use thereof | BAYER HEALTHCARE AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1414817-A1 | SUBSTITUTED ISOINDOLES AND E USE THEREOF | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011858-A1 | SUBSTITUTED ISOINDOLES AND E USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039446-A1 | Substituted isoindoles and their use | F2, F12, TFPI2 | F10 19/4885HTR1A 527/4885DRD2 1154/4885 |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | F2, F12, F5 | F10 14/4885HTR1A 580/4885DRD2 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.